Lung Cancer Tumor Testing: Setting the Stage
Justin F. Gainor, M.D., shares which lung cancer mutations have approved targeted therapies in this clip from our expert panel discussion on lung cancer tumor testing. For more information and to see the full recorded discussion, visit Lung.org/tumor-testing-videos.
Generously supported by AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, Pfizer, and Merck & Co., Inc.
Setting the stage to talk about lung cancer tumor testing
What we’re gonna talk about today in terms of tumor testing is the next level, and that is trying to understand some of the things we can’t always see, and that is the genes within those tumors and whether there are genetic changes, and we call those mutations. So, genes and DNA are the building blocks of life, and we know that in the field of lung cancer, it’s not just one disease. There are actually hundreds of different types of lung cancers and these are defined by different genetic changes. And this has bearing on how we treat lung cancer. We know that certain genetic changes allow us to use more targeted medicines that can have profound impact on a patient’s clinical course.
Page Last Updated: November 9, 2018
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.